adam8

ADAM8-IN-1 is a potent ADAM8 inhibitor with an IC 50 value of 73 nM.

JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively, and can be used to study the immune system of the body.

Cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of the metalloproteinase ADAM8, demonstrating an IC50 value of 182 nM. It has shown potential for application in the treatment of inflammatory diseases and cancer [1].

TMI-1 (WAY-171318), a novel orally active inhibitor of ADAM17 (TACE) and MMP, induces tumor apoptosis in a breast cancer.

Cyclo(RLsKDK) (BK-1361) serves as a targeted inhibitor of the metalloproteinase ADAM8, demonstrating efficacy with an IC50 value of 182 nM. This compound shows promise for use in the treatment of inflammatory diseases and cancer, highlighting its potential therapeutic applications.